A seven-page letter Mylan N.V. sent to Sen. Chuck Grassley, R-Iowa, detailing its justifications for the EpiPen price increases that have brought the company intense scrutiny doesn’t provide a “full picture,” he said Friday.
Grassley called Mylan’s answer to a series of questions he put forth in August an “incomplete response” that doesn’t track with the outrage Congress is hearing over the company’s roughly 500 percent price increase for the epinephrine auto-injector since it acquired the rights to the product in 2007.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
